Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

66.30 -0.33 (-0.50%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,151,621
Open 65.93
Bid (Size) 66.00 (1)
Ask (Size) 66.63 (1)
Prev. Close 66.63
Today's Range 65.93 - 66.50
52wk Range 60.47 - 87.67
Shares Outstanding N/A
Dividend Yield 1.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Achilles Therapeutics announces a $12M deal with AstraZeneca for TRACERx data and plans job cuts following its strategic review. 
Via Benzinga
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN
From The Rosen Law Firm, P.A.
Via Business Wire

Performance

YTD
-3.07%
-3.07%
1 Month
-0.15%
-0.15%
3 Month
-13.75%
-13.75%
6 Month
-16.87%
-16.87%
1 Year
-0.30%
-0.30%

More News

Read More
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption - Hagens Berman
Via NewMediaWire
Topics Fraud Law Enforcement
Exposures Legal
Is AstraZeneca Stock a Buy?
Via The Motley Fool
AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
Via Benzinga
Exposures Product Safety
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN
From Rosen Law Firm
Via Business Wire
Did AstraZeneca PLC Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - AZN
Via ACCESSWIRE
AZN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your AstraZeneca PLC investment
Via ACCESSWIRE
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Via ACCESSWIRE
3 Unstoppable Stocks to Buy Right Now
Via The Motley Fool
Shareholders that lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about Securities Fraud Investigation - AZN
Via ACCESSWIRE
AstraZeneca PLC INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by AstraZeneca PLC (AZN)
Via ACCESSWIRE
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Via Benzinga
Levi & Korsinsky Investigates Possible Securities Fraud Violations by AstraZeneca PLC (AZN)
Via ACCESSWIRE
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
Via Benzinga
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
From AstraZeneca
Via Business Wire
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
From AstraZeneca
Via Business Wire
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
From AstraZeneca
Via Business Wire
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Via Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Via Benzinga
Exposures Product Safety
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.